Clinical trials
Hematologic Diseases trials in Spain
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
59 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2007 | 1 |
| 2010 | 2 |
| 2012 | 2 |
| 2013 | 5 |
| 2014 | 7 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 5 |
| 2018 | 4 |
| 2019 | 4 |
| 2020 | 3 |
| 2021 | 8 |
| 2022 | 5 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 28 |
| Active, not recruiting | 13 |
| Recruiting | 8 |
| Terminated | 5 |
| Unknown status | 1 |
| Withdrawn | 1 |
| Enrolling by invitation | 1 |
| Not yet recruiting | 1 |
| No longer available | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 9 |
| Loxo Oncology, Inc. | 5 |
| Seagen Inc. | 5 |
| Takeda | 4 |
| Pfizer | 3 |
| Swedish Orphan Biovitrum | 3 |
| Abbott Medical Devices | 2 |
| Agios Pharmaceuticals, Inc. | 2 |
| BioMarin Pharmaceutical | 2 |
| Cogent Biosciences, Inc. | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hematologic Diseases | 59 |
| Hemorrhagic Disorders | 12 |
| Bone Marrow Diseases | 11 |
| Lymphoma, Non-Hodgkin | 11 |
| Leukemia | 10 |
| Lymphoma | 10 |
| Blood Coagulation Disorders | 9 |
| Myeloproliferative Disorders | 9 |
| Neoplasms | 9 |
| Immune System Diseases | 8 |
Trials
Showing 51 to 59 of 59. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.